An observational study in Medullary Thyroid Cancer (MTC) and Cultural Adaptation, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Carcinoma, Medullary with a site in United States — 12 open to participants now, 24 under way, 1 of them phase 3. Carcinoma, Medullary · United States.
Among the 81 studies in Carcinoma, Medullary with a site in United States, this one is the 10th largest by planned enrollment of the 10 observational ones that give a count, is one of 5 that started in 2025, is one of 10 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 75th registered.
144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.
Browse Carcinoma, Medullary studies →12 of the 81 studies in Carcinoma, Medullary with a site in United States are open now. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Canada, Japan and 1 more country
Ages 18–100
University of Arizona · Sites in United States
Ages 18–99
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 35 · Phase 3 4 · Phase 4 1
First in 1996; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 155 across 31 observational studies indexed under Carcinoma, Medullary.
Median enrollment 30 across the 66 interventional studies, 413 across the 10 observational. Of the 52 that completed or were terminated, 26 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 81 have an industry lead sponsor. The 10 most frequent:
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
M.D. Anderson Cancer Center has 8 studies filed under Carcinoma, Medullary — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Medullary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07259304University of Southern CaliforniaSocial Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | 2026-12-31 |
| NCT07713901Novo Nordisk A/SDatabase Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma | 2026-12-31 |
| NCT04467021ECOG-ACRIN Cancer Research GroupCancer and Blood Pressure Management, CARISMA Study | 2027-08-31 |
| NCT04759911M.D. Anderson Cancer CenterSelpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 81 studies in Carcinoma, Medullary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To find good information about medullary thyroid cancer that is easy to understand and reliable, so researchers aim to design some new educational materials to help.
Primary Objectives
Secondary Objectives
MD Anderson Cancer Center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Questionnaires/Survey Measures * Qualitative Instruments
Questionnaires/Survey Measures
Time frame: Through study completion; an average of 1 year
Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2026 → Mar 2028, on Sep 25, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.